Genmab — December 2022
-
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma https://www.prnewswire.com/news-releases/janssen-submits-biologics-license-application-to-us-fda-for-talquetamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-301699241.html
-
-
Preliminary activity is reported with an anti-IL-8 monoclonal antibody plus nivolumab in melanoma
Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors
(dailyreporter.esmo.org)
-
Godmorgen
Opdateret status oversigt for det Danske OMX C25 Index fra NordStock fredag d. 9. december - købs- og salgsignaler: https://www.proinvestor.com/boards/107957/ -
Volume på Genmab ADS var vist ekstraordinær høj i går - næsten 1.4 mill. omsat
-
Ret vildt at tænke på at når Epco og Talquetamab bliver godkendte i løbet af næste år, vil der være 8 Genmab udviklede produkter på markedet. Hvad mon bliver nr. 9. Mim8 fra Novo??
-
Enig GB. Det er vildt og imponerende.
-
Positive Early Results of Mim8 Pave Way for Testing in Phase 3 Trials https://hemophilianewstoday.com/news/mim8-well-tolerated-early-study-paving-way-phase-3-hemophilia-a-clinical-trials/
-
-
Exciting responses to bispecific epcoritamab for Richter's transformed CLL, which can be very tricky to treat https://twitter.com/eddie_cliff/status/1601717217082900480?s=61&t=XzZjo9n9cJC0DuYLqTWXUw
-
Godmorgen.
Bulder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind